Pre-made Elgemtumab biosimilar ( Whole mAb, anti-ERBB3 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-170
Anti-ERBB3 therapeutic antibody (Pre-made Elgemtumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Elgemtumab, also known as LJM716, is a high- affinity IgG1�� type monoclonal antibodies selected from a Human Combinatorial Antibody Library (HuCAL). It can specifically bind to ERBB3 to neutralize multiple modes of ERBB3 activation.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ERBB3 therapeutic antibody (Pre-made Elgemtumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||4p59:HL|
|Companies||MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology|
|Conditions Discontinued||Breast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours|
|Development Tech||Medarex HuMAb Mouse|